CRISPR and other new technologies open doors for drug development, but which diseases get prioritized? It comes down to money and science
Drug development takes a great deal of time, money and effort. While future profits play a big factor in which diseases gets prioritized, advocacy and research incentives can also tilt the scale.
C. Michael White, Distinguished Professor of Pharmacy Practice, University of Connecticut •
conversation
Dec. 14, 2023 • ~10 min
Dec. 14, 2023 • ~10 min
Horseshoe crab blood is vital for testing intravenous drugs, but new synthetic alternatives could mean pharma won't bleed this unique species dry
Horseshoe crabs play a unique role in medicine, but they’re also ecologically important in their home waters along the Atlantic coast. Can regulators balance the needs of humans and nature?
Jolie Crunelle, Master's Degree Student in Science, Technology, and Public Policy, Rochester Institute of Technology •
conversation
Oct. 12, 2023 • ~10 min
Oct. 12, 2023 • ~10 min
Blame capitalism? Why hundreds of decades-old yet vital drugs are nearly impossible to find
The shortages, which have been going on for years, have typically affected only low-cost generics rather than profitable brand-name drugs.
Geoffrey Joyce, Director of Health Policy, USC Schaeffer Center, and Associate Professor, University of Southern California •
conversation
July 20, 2023 • ~9 min
July 20, 2023 • ~9 min
'From Magic Mushrooms to Big Pharma' – a college course explores nature's medicine cabinet and different ways of healing
An anthropology course explores how peoples and cultures around the world use nature-based medicines to heal.
Heather McIlvaine-Newsad, Professor of Anthropology, Western Illinois University •
conversation
June 9, 2023 • ~6 min
June 9, 2023 • ~6 min
/
8